Related Experiment Video
Updated: Dec 6, 2025

10:37
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
3.3K
Variations in Hepatitis B Vaccine Series Completion by Setting Among Adults at Risk in West Virginia
Stacy Tressler1, Christa Lilly2, Diane Gross1
1Department of Epidemiology, West Virginia University, Morgantown, West Virginia; Monongalia County Health Department, Morgantown, West Virginia.
American Journal of Preventive Medicine
|October 5, 2020
Summary
West Virginia
Area of Science:
- Public Health
- Infectious Disease Epidemiology
- Vaccinology
Background:
- West Virginia faces the highest rate of acute hepatitis B in the U.S.
- A pilot project aimed to increase hepatitis B vaccination among at-risk adults.
- Over 10,000 vaccine doses were distributed across various settings.
Purpose of the Study:
- To identify which vaccination setting is most effective for completing the hepatitis B vaccine series.
- To analyze the likelihood of receiving 2 or 3 doses based on the vaccination location.
Main Methods:
- Retrospective cohort study analyzing data from 2013-2015.
- Participant data extracted and analyzed in 2019.
- Bivariate, multivariable, and mixed-effects regression models used to calculate odds.
Main Results:
- Vaccination at substance use treatment centers and family planning clinics increased the likelihood of receiving the 3-dose series.
- Substance use treatment centers, correctional facilities, and family planning clinics were associated with higher odds of receiving at least 2 doses.
Conclusions:
- Targeted hepatitis B vaccination strategies in family planning clinics, substance use treatment centers, and correctional facilities can improve vaccine completion rates.
- These settings show promise for increasing hepatitis B vaccine uptake in high-risk populations.
Related Concept Videos
Cross-reactivity
32.5K
Overview
32.5K
Bioequivalence studies: Biowaivers
107
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
107
Vaccinations
50.5K
Overview
50.5K
Bioavailability Study Design: Healthy Subjects Versus Patients
70
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
70

